anetumab ravtansine + gemcitabine

Anetumab ravtansine + gemcitabine is a combination investigational therapy for the treatment of mesothelin-expressing advanced solid tumors, including pancreatic adenocarcinoma and cholangiocarcinoma. Anetumab ravtansine is an antibody-drug conjugate (ADC) composed of a fully human IgG1 antibody targeting the cell-surface glycoprotein mesothelin, conjugated via a cleavable disulfide linker to the cytotoxic antimitotic agent DM4 (a maytansinoid). After binding to mesothelin on tumor cells, the complex is internalized, releasing DM4 to disrupt microtubule function and induce apoptosis. Gemcitabine is a nucleoside analog (antimetabolite) and DNA synthesis inhibitor that is commonly used in the treatment of solid tumors. The combination aims to exploit both targeted cytotoxic delivery and DNA synthesis inhibition in mesothelin-positive cancers. Developed primarily for the treatment of advanced pancreatic adenocarcinoma and cholangiocarcinoma, this regimen has been studied in phase I/1b clinical trials to assess safety, dosing, and preliminary antitumor activity[1][3][5][7][9].